ATE518884T1 - Spezifisch an chemokin beta-4 bindende antikörper - Google Patents

Spezifisch an chemokin beta-4 bindende antikörper

Info

Publication number
ATE518884T1
ATE518884T1 AT03721955T AT03721955T ATE518884T1 AT E518884 T1 ATE518884 T1 AT E518884T1 AT 03721955 T AT03721955 T AT 03721955T AT 03721955 T AT03721955 T AT 03721955T AT E518884 T1 ATE518884 T1 AT E518884T1
Authority
AT
Austria
Prior art keywords
antibodies
immune system
well
system diseases
disease
Prior art date
Application number
AT03721955T
Other languages
English (en)
Inventor
Craig Rosen
Steven Ruben
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Application granted granted Critical
Publication of ATE518884T1 publication Critical patent/ATE518884T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT03721955T 2002-05-01 2003-04-30 Spezifisch an chemokin beta-4 bindende antikörper ATE518884T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37656102P 2002-05-01 2002-05-01
PCT/US2003/013414 WO2003092597A2 (en) 2002-05-01 2003-04-30 Antibodies that specifically bind to chemokine beta-4

Publications (1)

Publication Number Publication Date
ATE518884T1 true ATE518884T1 (de) 2011-08-15

Family

ID=29401362

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03721955T ATE518884T1 (de) 2002-05-01 2003-04-30 Spezifisch an chemokin beta-4 bindende antikörper

Country Status (6)

Country Link
US (3) US7375192B2 (de)
EP (1) EP1534752B1 (de)
AT (1) ATE518884T1 (de)
AU (1) AU2003225237A1 (de)
CA (1) CA2484121A1 (de)
WO (1) WO2003092597A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1539235A2 (de) 2002-07-01 2005-06-15 Human Genome Sciences, Inc. Spezifisch an reg iv bindende antikörper
US8444973B2 (en) 2005-02-15 2013-05-21 Duke University Anti-CD19 antibodies and uses in B cell disorders
US20060263357A1 (en) * 2005-05-05 2006-11-23 Tedder Thomas F Anti-CD19 antibody therapy for autoimmune disease
TWI417301B (zh) * 2006-02-21 2013-12-01 Wyeth Corp 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
US7943328B1 (en) 2006-03-03 2011-05-17 Prometheus Laboratories Inc. Method and system for assisting in diagnosing irritable bowel syndrome
WO2008021263A2 (en) * 2006-08-11 2008-02-21 Medarex, Inc. Methods of indentifying antibodies that bind oligomeric forms of chemokines and uses thereof
US20080085524A1 (en) * 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
US20100094560A1 (en) * 2006-08-15 2010-04-15 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
JP5211790B2 (ja) * 2007-03-26 2013-06-12 住友化学株式会社 Ｄｎａメチル化測定方法
WO2009026117A2 (en) * 2007-08-16 2009-02-26 Glaxo Group Limited Novel compounds
JP2012197228A (ja) * 2009-07-27 2012-10-18 Kyoto Univ 肝炎の治療剤もしくは予防剤
NZ611269A (en) 2010-11-19 2015-03-27 Eisai R&D Man Co Ltd Neutralizing anti-ccl20 antibodies
US8715572B2 (en) 2011-05-19 2014-05-06 Abbott Laboratories Method and apparatus for detection, analysis, and collection of rare cellular events

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897348A (en) 1983-08-25 1990-01-30 Sri International Recombinant materials and methods for producing human connective tissue-activating peptide-III and analogs thereof
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
CH681625A5 (de) 1988-12-08 1993-04-30 Sandoz Ag
US5212073A (en) 1989-05-12 1993-05-18 Genetics Institute, Inc. Process for producing human JE cytokine
US5179078A (en) 1989-05-12 1993-01-12 Dana Farber Cancer Institute Method of suppressing tumor formation in vivo
DE69020573T3 (de) 1989-09-25 1999-12-16 Crc Technology Ltd., London Verfahren zur wachstumshemmung von stammzellen.
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
NZ237202A (en) 1990-02-23 1994-01-26 Bristol Myers Squibb Co Composition containing beta-lactam antibiotic and cationic oligopeptide
JPH06503710A (ja) 1990-09-14 1994-04-28 カイロン　コーポレイション 酵母細胞におけるマクロファージ誘導タンパク質（ｍｉｐ）の発現
US6001649A (en) 1990-11-29 1999-12-14 Societe Anonyme: Elf Sanofi Chemokine NC28 (monocyte chemotactic protein-3, MCP-3) polypeptides and their recombinant production
US5401651A (en) 1991-10-16 1995-03-28 Walz; Alfred DNA encoding ENA-78, a neutrophil activating factor
US5306709A (en) 1991-11-15 1994-04-26 The University Of Pennsylvania Suppression of megakaryocytopoiesis by macrophage inflammatory proteins
US5413778A (en) 1992-10-05 1995-05-09 The Regents Of The University Of Michigan Labelled monocyte chemoattractant protein material and medical uses thereof
US5346686A (en) 1992-10-05 1994-09-13 Mallinckrodt Medical, Inc. Labelled interleukin-8 and medical uses thereof
US5474983A (en) 1993-03-15 1995-12-12 The Research Foundation Of State University Of New York Method of inhibiting pro-inflammatory mediator release from basophils and mast cells
JPH0789866A (ja) 1993-09-21 1995-04-04 Nippon Kayaku Co Ltd 感染防御剤
JP3677288B2 (ja) 1993-12-22 2005-07-27 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド マクロファージ炎症蛋白質−３、−４および−１▲下γ▼
JPH10500301A (ja) 1994-05-16 1998-01-13 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド マクロファージ遊走阻止因子−３
DE69428460T2 (de) 1994-05-16 2002-05-23 Human Genome Sciences, Inc. Chemotaktisches protein
ES2235172T3 (es) 1994-08-23 2005-07-01 Human Genome Sciences, Inc. Quimioquina humana beta-9.
WO1996005856A1 (en) 1994-08-23 1996-02-29 Human Genome Sciences, Inc. Human chemokine polypeptides
US6174995B1 (en) 1994-08-23 2001-01-16 Haodong Li Human chemokines, CKβ4 and CKβ10/MCP-4
WO1996009062A1 (en) 1994-09-23 1996-03-28 University Of Nebraska Board Of Regents Polypeptide agonists and antagonists of human interleukin-8
US5602008A (en) 1994-11-29 1997-02-11 Incyte Pharmaceuticals, Inc. DNA encoding a liver expressed chemokine
AU723891B2 (en) 1995-06-05 2000-09-07 Human Genome Sciences, Inc. Human chemokine beta-11 and human chemokine alpha-1
WO1996039520A1 (en) 1995-06-06 1996-12-12 Human Genome Sciences, Inc. Human chemokine beta-12
WO1996039521A1 (en) 1995-06-06 1996-12-12 Human Genome Sciences, Inc. Human chemokine beta-13
ZA968896B (en) 1995-10-24 1997-04-24 Smithkline Beecham Corp Method of mobilizing hematopoietic stem cells
WO1997015594A1 (en) 1995-10-24 1997-05-01 Smithkline Beecham Corporation Novel chemokine for mobilizing stem cells
EP0885293B1 (de) 1996-02-23 2006-06-07 Human Genome Sciences, Inc. Menschliche chemokin-polypeptide.
JP2000508527A (ja) 1996-03-27 2000-07-11 アイコス コーポレイション 単球走化性タンパク質―５物質及び方法
EP0909321A2 (de) 1996-07-05 1999-04-21 Schering Corporation Chemokin reagenzien aus saeugetieren
GB9617923D0 (en) 1996-08-28 1996-10-09 Smithkline Beecham Plc Novel receptor
AU4243097A (en) 1996-09-10 1998-04-02 Schering Corporation Mammalian chemokines, related reagents
WO1998014573A1 (en) 1996-09-30 1998-04-09 The General Hospital Corporation Mcp-4 and mcp-5: novel chemokines
WO1998017800A1 (fr) 1996-10-17 1998-04-30 Shionogi & Co., Ltd. Larc, nouvelle chimiokine cc humaine
CA2242384A1 (en) 1996-11-15 1998-05-22 Indiana University Foundation Exodus chemokine materials and methods
WO1999047674A2 (en) 1998-03-18 1999-09-23 Corixa Corporation Compounds and methods for therapy and diagnosis of lung cancer
EP1149113A1 (de) * 1999-02-03 2001-10-31 Schering Corporation Verwendung von agonisten oder antagonisten von mip-3a in der therapie

Also Published As

Publication number Publication date
EP1534752A4 (de) 2006-08-09
EP1534752A2 (de) 2005-06-01
US7943741B2 (en) 2011-05-17
EP1534752B1 (de) 2011-08-03
US7375192B2 (en) 2008-05-20
WO2003092597A2 (en) 2003-11-13
AU2003225237A1 (en) 2003-11-17
US20080233134A1 (en) 2008-09-25
CA2484121A1 (en) 2003-11-13
WO2003092597A3 (en) 2005-03-31
AU2003225237A8 (en) 2003-11-17
US20110223178A1 (en) 2011-09-15
US20060275210A1 (en) 2006-12-07

Similar Documents

Publication Publication Date Title
MXPA03010747A (es) Anticuerpos que se unen inmunoespecificamente a receptores de ligando inductor de apoptosis relacionado con factor de necrosis tumoral.
WO2003054216A3 (en) Antibodies that immunospecifically bind to trail receptors
ATE330967T1 (de) An her2 bindende peptidverbindungen
WO2003089575A3 (en) Antibodies that specifically bind to tl5
DK0910647T3 (da) Human DNase i hyperaktive varianter
ATE518884T1 (de) Spezifisch an chemokin beta-4 bindende antikörper
WO2004000997A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2004013287A3 (en) Antibodies against c3a receptor
EA201201067A1 (ru) Способ получения связывающей молекулы, специфичной к белку, ассоциированному с расстройством, или антитела, или его связывающего фрагмента, или по меньшей мере одной цепи иммуноглобулина, связывающих вышеуказанный белок (варианты), связывающая молекула, антитело, цепь иммуноглобулина или их связывающий фрагмент (варианты), полинуклеотид, вектор и клетка-хозяина, их включающая композиция
DE3856180D1 (de) Nukleinsaürefragmente, die mannose bindende fragmente vom menschlichen mannosebindenden protein kodieren
WO2003102136A3 (en) Antibodies that specifically bind to neurokinin b
WO2004003144A3 (en) Antibodies that specifically bind to reg iv
WO2003080856A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2003085093A3 (en) Antibodies that specifically bind to gmad
WO2005016236A3 (en) Antibodies that immunospecifically bind to trail receptors
WO2004016753A3 (en) Antibodies that immunospecifically bind to trail receptors
WO2003086301A3 (en) Antibodies that specifically bind to tr2
WO2003078572A3 (en) Therapeutic polypeptides, nucleic acids encoding same and methods of use
WO2003042367A3 (en) Antibodies that immunospecifically bind to trail receptors
WO2003022998A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2002079377A3 (en) Antibodies that immunospecifically bind to trail receptors
WO2003040329A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2003085124A8 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
ES2188653T3 (es) Variantes de la dnasa i humana.
WO2003085096A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties